Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancreatic Parenchymal Injection of N-Butyl-2-Cyanoacrylate for Pancreaticojejunostomy After Pancreaticoduodenectomy
NCT07132541Phase 1Recruiting
- Sponsor
- Minia University
- Start
- Aug 2025
- Primary completion
- Nov 2026
- Modality
- Injectable Hydrogels, Transdermal Patches
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of N-butyl-2-cyanoacrylate in pancreatic fistula (POPF), sponsored by Minia University. Primary endpoint: Incidence of postoperative pancreatic fistula at 10 days. Started Aug 2025; status: recruiting.
02
Drugs
N-butyl-2-cyanoacrylate
03
Conditions
pancreatic fistula (POPF)
Beyond the preview
Go deeper on NCT07132541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07132541.